Unibest

Pharmaceutical intermediates

Maribavir Intermediates

4 pharmaceutical intermediates for Maribavir. Indication: Cytomegalovirus Infection.

提交项目All intermediates

About Maribavir

Originator
GlaxoSmithKline
Indication
Cytomegalovirus Infection
Approved Date
11/23/2021
NCE Patent
11/23/2026
DS/DP
01/04/2032

Available intermediates

4 intermediates currently listed for Maribavir. Request specifications, documentation or a quotation for any item below.

Maribavir intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
BENZIMIDAVIR176161-24-3//
1,2,3,5-TETRA-O-ACETYL-BETA-L-RIBOFURANOSE144490-03-9//
2-BROMO-5,6-DICHLOROBENZIMIDAZOLE142356-40-9//
4,5-Dichloro-1,2-benzenediamine5348-42-5//

Other programs under M

MaxacalcitolMetoclopramide HClMicafungin SodiumMilvexianMirogabalin besilateMolnupiravirMomelotinib Dihydrochloride MonohydrateMoxifloxacin hydrochloride

Building toward Maribavir?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →